¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"active immunity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active phase
    Ȱ¼º±â
  • active placebo
    Ȱ¼º¼ÓÀÓ¾à
  • active prosthesis
    Ȱµ¿ÀÇÁö, ´Éµ¿ÀÇÁö
  • active shielding
    ´Éµ¿Â÷Æó
  • active shimming
    ´Éµ¿º¸Á¤
  • active site
    Ȱ¼ººÎÀ§
  • active transport
    ´Éµ¿¿î¹Ý
  • active treatment
    Àû±ØÄ¡·á
  • active tuberculosis
    Ȱµ¿°áÇÙ
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿°£¿°
  • chronic active photosensitive dermatitis
    ¸¸¼ºÈ°¼º±¤¼±°ú¹ÎÇǺο°
  • MR active nuclei
    ÀÚ±â°ø¸íȰ¼ºÇÙ
  • surface-active disinfectant
    Ç¥¸éȰ¼º¼Òµ¶Á¦
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antitoxic immunity
    Ç×µ¶¼Ò¸é¿ª
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active prosthesis
    Ȱµ¿ÀÇÁö, ´Éµ¿ÀÇÁö
  • active shielding
    ´Éµ¿°¡¸², ´Éµ¿Â÷Æó
  • active shimming
    ´Éµ¿º¸Á¤
  • active site
    Ȱ¼ººÎÀ§
  • active transport
    ´Éµ¿¿î¹Ý
  • active treatment
    Àû±ØÄ¡·á
  • active tuberculosis
    Ȱµ¿°áÇÙ
  • active gradient shielding
    ´Éµ¿±â¿ï±âÂ÷Æó, ´Éµ¿°æ»çÂ÷Æó
  • active incorporative mode
    Àû±ØÇÔÀÔ¾ç½Ä
  • chronic active photosensitive dermatitis
    ¸¸¼ºÈ°¼º±¤¼±°ú¹ÎÇǺο°
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿°£¿°
  • surface-active disinfectant
    Ç¥¸éȰ¼º¼Òµ¶Á¦, °è¸éȰ¼º¼Òµ¶Á¦
  • metabolically active stone
    ´ë»çȰ¼ºµ¹
  • MR active nuclei
    ÀÚ±â°ø¸íȰ¼ºÇÙ
  • acquired immunity
    ÈÄõ¸é¿ª
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • active immunization
    ´Éµ¿¸é¿ª¹ý, ´Éµ¿¸é¿ªÁ¶Ä¡
  • active incorporative mode
    Àû±ØÀû ÇÔÀÔ ¾ç½Ä
  • active marrow
    Àû°ñ¼ö.
  • active material
    Ȱ¼º¹°Áú(üÀàõÚªòõ).
  • active movement
    ´Éµ¿¿îµ¿(ÒöÔÑê¡ÔÑ)
  • active negativism
    Àû±Ø¼º °ÅÀýÁõ.
  • active oxygen
    Ȱ¼º»ê¼Ò(üÀàõß«áÈ).
  • active shielding
    ´Éµ¿ Â÷Æó
  • active shimming
    ´Éµ¿ º¸Á¤
  • active site
    Ȱ¼ºÀÚ¸®.
  • active spot
    Ȱ¼ºÁ¡(üÀàõïÇ).
  • active tension
    ´Éµ¿Àå·Â(ÒöÔÑíåæ³)
  • active transport
    ´Éµ¿(Àû)¿î¹Ý(¡­îÜê¡Úæ), ´Éµ¿(Àû)¼ö¼Û(ÒöÔÑîÜâÃáê)
  • active treatment
    Á÷Á¢Ä¡·á, Àû±Ø¿ä¹ý(îÝпèþÛö).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • active incorporative mode
    Àû±ØÀû ÇÔÀÔ ¾ç½Ä
  • active marrow
    Àû°ñ¼ö.
  • active material
    Ȱ¼º¹°Áú(üÀàõÚªòõ).
  • active movement
    ´Éµ¿¿îµ¿(ÒöÔÑê¡ÔÑ)
  • active negativism
    Àû±Ø¼º °ÅÀýÁõ.
  • active oxygen
    Ȱ¼º»ê¼Ò(üÀàõß«áÈ).
  • active shielding
    ´Éµ¿ Â÷Æó
  • active shimming
    ´Éµ¿ º¸Á¤
  • active site
    Ȱ¼ºÀÚ¸®.
  • active spot
    Ȱ¼ºÁ¡(üÀàõïÇ).
  • active tension
    ´Éµ¿Àå·Â(ÒöÔÑíåæ³)
  • active transport
    ´Éµ¿(Àû)¿î¹Ý(¡­îÜê¡Úæ), ´Éµ¿(Àû)¼ö¼Û(ÒöÔÑîÜâÃáê)
  • active treatment
    Á÷Á¢Ä¡·á, Àû±Ø¿ä¹ý(îÝпèþÛö).
  • active tuberculosis
    Ȱµ¿¼º °áÇÙ(Áõ)(üÀÔÑàõÌ¿ú·ñø).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • transferred immunity
    ÀüÀÌ ¸é¿ª (ï®ì¹Øóæ¹)
  • transplantation immunity
    ÀÌ½Ä ¸é¿ª(ì¹ãÕØóæ¹)
  • active acetaldehyde
    Ȱ¼º(üÀàõ) ¾Æ¼¼Æ®¾Ëµ¥ÇÏÀ̵å
  • active acetate
    Ȱ¼º¾Æ¼¼Æ®»ê¿°(ß«ç¤)
  • active acetyl
    Ȱ¼º(üÀàõ)¾Æ¼¼Æ¿
  • active acyl
    Ȱ¼º (üÀàõ)¾Æ½Ç
  • active adenocyl
    Ȱ¼º(üÀàõ) ¾Æµ¥³ë½Ç
  • active adenylate
    Ȱ¼º ¾Æµ¥´Ò»ê¿° (ß«ç¤)
  • active aldehyde
    Ȱ¼º(üÀàõ)¾Ëµ¥ÇÏÀ̵å
  • active aldehyde theory
    Ȱ¼º(üÀàõ)¾Ëµ¥ÇÏÀ̵å·Ð(Öå)
  • active amino acid
    Ȱ¼º(üÀàõ)¾Æ¹Ì³ë»ê (ß«)
  • active anaphylaxis
    Ȱ¼º(üÀàõ)¾Æ³ªÇʶô½Ã½º
  • active carbohydrate
    Ȱ¼º´çÁú (üÀàõÓØòõ)
  • active carbon
    Ȱ¼ºÅº (üÀàõ÷©)
  • active carbon dioxide
    Ȱ¼ºÀÌ»êȭź¼Ò (üÀàõì£ß«ûù÷©áÈ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CIDS cellular immunity deficiency syndrome; circular intensity differential scattering; continuous insuli...
CMI carbohydrate metabolism index; care management integration; case mix index; cell-mediated immunity; ...
HI half-scan with interpolation; head injury; health insurance; hearing impaired; heart infusion; hemag...
immun immune, immunity, immunization
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ACA Active cutaneous anaphylaxis
AO Active oxygen
AOF Active oxygen forms
AOS Active oxygen species
AR Active renin
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • natural immunity
    ÀÚ¿¬ ¸é¿ª
  • phagocytic immunity
    ½Ä¼¼Æ÷¼º ¸é¿ª
  • racial immunity
    ¹ÎÁ· ¸é¿ª
    À¯ÀüÀûÀ¸·Î °áÁ¤µÇ¾î ÀÖ´Â ÀúÇ×¼ºÀ¸·Î, ¾î¶² Á¾Á· ¸ðµÎ ¶Ç´Â °ÅÀÇ ÀüºÎ°¡ ¾î¶² Á¾·ùÀÇ °£¿°¿¡ ´ëÇÏ¿© ³ªÅ¸³ª´Â ¸é¿ª »óÅÂ.
  • specific humoral immunity
    ƯÀ̼º ü¾× ¸é¿ª
  • transplantation immunity
    ÀÌ½Ä ¸é¿ª
  • active
    Ȱ¼º, Ȱµ¿¼º, ´Éµ¿¼º
    ÀÛ¿ë, Ȱµ¿, ÇàÀ§¸¦ Ư¡À¸·Î Çϸç, ¼öµ¿ÀûÀÌ ¾Æ´Ñ °Í.
  • active acupuncture locus
    Ȱµ¿¼º °æÇ÷ Á¡
  • active coefficient
    Ȱ¼ºµµ °è¼ö
    ¹°ÁúÀÇ ³óµµ°¡ ³·À» ¶§¿¡ ¹ÝÀÀ·ÂÀº ³óµµ¿¡ ºñ·ÊÇϴµ¥ ³óµµ°¡ ³ô¾ÆÁ³À» ¶§´Â ¹ÝÀÀ·ÂÀÌ °¨¼ÒµÇ°í, ³óµµ¿¡ Ȱµ¿°è¼ö¸¦ °öÇÑ °Í¿¡ ºñ·ÊÇØ¼­ ¹ÝÀÀ·ÂÀÌ ³ªÅ¸³­´Ù.
  • active eruption
    Ȱ¼º ¸ÍÃâ, ´Éµ¿Àû ¸ÍÃâ
    1. ¸Å¸ôµÇ¾î ÀÖ´ø Ä¡¾Æ°¡ »ý¸®ÀûÀ¸·Î ´ëÇÕÄ¡ÀÇ ±³ÇÕ¸é±îÁö ¸ÍÃâÇϰųª ¸ÍÃâµÈ Ä¡¾Æ°¡ ¸¶¸ðµÈ °í°æ¸¸Å­ º¸»óÇϱâ À§ÇØ ¸ÍÃâÇÏ´Â Çö»ó. 2. Ä¡¾Æ°¡ ±³ÇÕÁ¢ÃËÀ» ÀÌ·é ÈÄ, ±³ÇÕÆò¸é ¹æÇâÀ¸·Î ´Éµ¿Àû À̵¿À» º¸ÀÌ´Â °Í.
  • active exercise program
    Àû±ØÀû ¿îµ¿
  • active gradient shielding
    ´Éµ¿ °æ»çÂ÷Æó
  • active hydrogen
    Ȱ¼º ¼ö¼Ò
  • active mandibular opening
    ´Éµ¿ ÇÏ¾Ç °³±¸
    ±æÇ×±Ù
  • active material
    Ȱ¼º ¹°Áú
    È­ÇÐ ¹ÝÀÀ¿¡ À־ Ã˸ÅÀÇ ¹ÝÀÀ ÃËÁø ´É·ÂÀ» Ȱ¼ºÈ­ ½ÃŰ´Â ¹°Áú.
  • active myofascial trigger point
    Ȱµ¿¼º ±Ù¸· ¹ßÅëÁ¡
    ÃËÁøÀ» ÅëÇØ ÀÚ±ØÀ» ÁÖÁö ¾Ê´õ¶óµµ ±¹¼ÒÀûÀ̰ųª ÀüÀÌµÈ ÅëÁõÀ̳ª Áõ»óÀ» ³ªÅ¸³»´Â ±Ù¸· ¹ßÅëÁ¡.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
cellular immunity deficiency syndrome <syndrome> A syndrome marked by increased susceptibility to infection, especially to viral infection, associated with defective functioning of the mechanism responsible for acquired immunity of the cell-mediated kind.
See: immunodeficiency.
(05 Mar 2000)
group immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
concomitant immunity The paradoxical immune status in which resistance to reinfection coincides with the persistence of the original infection.
Synonym: concomitant immunity.
(05 Mar 2000)
herd immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
humoral immunity <immunology> A form of immunity whereby B lymphocytes and plasma cells produce antibodies to foreign agents (antigens) and stimulate T lymphocytes to attack them (cellular immunity).
These antibodies also stimulate the release of chemical mediators (for example interferon, complement) which enhance antigen destruction.
(06 Mar 1998)
specific immunity The immune status in which there is an altered reactivity directed solely against the antigenic determinants (infectious agent or other) that stimulated it.
See: acquired immunity.
(05 Mar 2000)
specific passive immunity See: acquired immunity.
(05 Mar 2000)
natural immunity This includes local barriers to infection such as skin, stomach acid, mucous, the cough reflex, enzymes in tears and saliva and skin oils.
(27 Sep 1997)
natural passive immunity Immunity conferred by the mother on the foetus or newborn.
(14 Nov 1997)
stress immunity Insusceptibility or resistance to the effects of emotional strain.
(05 Mar 2000)
immunity <immunology> The condition of being immune, the protection against infectious disease conferred either by the immune response generated by immunisation or previous infection or by other nonimmunologic factors.
Origin: L. Immunitas
(13 Oct 1997)
immunity, cellular Those manifestations of the immune response which are mediated by antigen-sensitised T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
(12 Dec 1998)
immunity deficiency Inabillity to mount a normal immune response. Immunodeficiency can be due to a genetic disease or acquired as in aids due to HIV.
(12 Dec 1998)
immunity, maternally-acquired Resistance to a disease-causing agent induced by the introduction of maternal immunity into the foetus by transplacental transfer or into the neonate through colostrum and milk.
(12 Dec 1998)
immunity, mucosal Nonsusceptibility to the pathogenic effects of foreign microorganisms or antigenic substances as a result of antibody secretions of the mucous membranes. Mucosal epithelia in the gastrointestinal, respiratory, and reproductive tracts produce a form of IgA (IgA, secretory) that serves to protect these ports of entry into the body.
(12 Dec 1998)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
active immunity A type of acquired immunity whereby resistance to a disease is built up by either having the disease or receiving a vaccine against it.
Ãâó: www.kurlama.com/glossary/a.html
active immunity Immunity produced by the person’s own immune system. This type of immunity can be brought about by a natural infection or by a vaccine. It is usually long lasting. (Compare with passive immunity.)
Ãâó: www.gulflink.osd.mil/va/va_taba.htm
active immunity immunity produced by an encounter with an antigen; provides immunologic memory.
Ãâó: paramedicine.wikispaces.org/Medical+Terminology
active immunity The body produces it's own antibodies or killer T Cells
Ãâó: www.edu.pe.ca/threeoaks/science/grassroots/bio521/...
active immunity Resistance developed in response to stimulus by an antigen (infecting agent or vaccine) and usually characterized by the presence of antibody produced by the host. See also host. Compare passive immunity.
Ãâó: www.merrea.org/glossary.html
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á